Charles L Rice

US Patent:

6943246, Sep 13, 2005

Filed:

May 30, 2002

Appl. No.:

10/158314

Inventors:

Charles M. Rice - University City MO, US
Alexander A. Kolykhalov - St. Louis MO, US

Assignee:

Washington University - St. Louis MO

International Classification:

C07H071/04
A61K039/29

US Classification:

536 241, 4242281

Abstract:

The invention relates to the discovery of a novel RNA sequence at the 3′ terminal sequence of hepatitis C virus (HCV) genome RNA. Included in the invention are the 3′ sequence, its complement, and their use for nucleic-acid based diagnostics and for developing and evaluating novel anti-HCV therapies. This sequence element, which is conserved among HCV genotypes, is likely to be essential for viral replication, and required for construction of full-length HCV cDNA clones capable of yielding infectious RNA, progeny virus or replication-competent HCV replicons. Such functional clones are useful tools for evaluation of therapeutic approaches and as substrates for developing candidate attenuated or inactivated HCV derivatives for vaccination against HCV.

US Patent:

7235394, Jun 26, 2007

Filed:

Nov 6, 2003

Appl. No.:

10/704407

Inventors:

Charles M. Rice - University City MO, US
Alexander A. Kolykhalov - St. Louis MO, US

Assignee:

Washington University - St. Louis MO

International Classification:

C12N 7/00
C12N 7/02
C12N 5/10
C12P 21/00
C07H 21/04

US Classification:

435239, 435 691, 435 701, 435325, 4353201, 4352351, 536 2372, 536 241

Abstract:

The present invention relates to the determination of an authentic HCV genome RNA sequences, to construction of infectious HCV DNA clones, and to use of the clones, or their derivatives, in therapeutic, vaccine, and diagnostic applications. The invention is also directed to HCV vectors, e. g. , for gene therapy of gene vaccines.

US Patent:

20030017586, Jan 23, 2003

Filed:

Jun 13, 2001

Appl. No.:

09/880567

Inventors:

Charles Rice - University City MO, US
Alexander Kolykhalov - St. Louis MO, US

Assignee:

Washington University

International Classification:

C12Q001/70
C07H021/04
C12Q001/68
C07H021/02
C12N005/08

US Classification:

435/366000, 435/005000, 536/023720, 435/370000, 435/006000, 536/023100, 536/024300, 536/024330

Abstract:

The invention relates to the discovery of a novel RNA sequence at the 3′ terminal sequence of hepatitis C virus (HCV) genome RNA. Included in the invention are the 3′ sequence, its complement, and their use for nucleic-acid based diagnostics and for developing and evaluating novel anti-HCV therapies. This sequence element, which is conserved among HCV genotypes, is likely to be essential for viral replication, and required for construction of full-length HCV cDNA clones capable of yielding infectious RNA, progeny virus or replication-competent HCV replicons. Such functional clones are useful tools for evaluation of therapeutic approaches and as substrates for developing candidate attenuated or inactivated HCV derivatives for vaccination against HCV.

US Patent:

20030027130, Feb 6, 2003

Filed:

Jun 13, 2001

Appl. No.:

09/880508

Inventors:

Charles Rice - University City MO, US
Alexander Kolykhalov - St. Louis MO, US

Assignee:

Washington University

International Classification:

C12Q001/70
C07H021/04
C12Q001/68
C07H021/02
A61K039/29

US Classification:

435/005000, 536/023720, 435/006000, 536/023100, 536/024100, 536/024300, 536/024330, 424/228100

Abstract:

The invention relates to the discovery of a novel RNA sequence at the 3′ terminal sequence of hepatitis C virus (HCV) genome RNA. Included in the invention are the 3′ sequence, its complement, and their use for nucleic-acid based diagnostics and for developing and evaluating novel anti-HCV therapies. This sequence element, which is conserved among HCV genotypes, is likely to be essential for viral replication, and required for construction of full-length HCV cDNA clones capable of yielding infectious RNA, progeny virus or replication-competent HCV replicons. Such functional clones are useful tools for evaluation of therapeutic approaches and as substrates for developing candidate attenuated or inactivated HCV derivatives for vaccination against HCV.

US Patent:

20030028010, Feb 6, 2003

Filed:

Nov 28, 2001

Appl. No.:

09/995937

Inventors:

Charles Rice - University City MO, US
Alexander Kolykhalov - St. Louis MO, US

Assignee:

Washington University

International Classification:

A61K039/12
C07H021/04
C12N007/01

US Classification:

536/023720, 435/235100, 424/186100

Abstract:

The present invention relates to the determination of an authentic HCV genome RNA sequences, to construction of infectious HCV DNA clones, and to use of the clones, or their derivatives, in therapeutic, vaccine, and diagnostic applications. The invention is also directed to HCV vectors, e.g., for gene therapy of gene vaccines.

US Patent:

20030073080, Apr 17, 2003

Filed:

Jul 27, 2001

Appl. No.:

09/917563

Inventors:

Charles Rice - University City MO, US
Alexander Kolykhalov - St. Louis MO, US

Assignee:

Washington University

International Classification:

C12Q001/70
C12Q001/68
C07H021/04
A61K039/29
C12N005/06

US Classification:

435/006000, 435/005000, 536/023720, 424/228100, 435/325000

Abstract:

The present invention relates to the determination of an authentic HCV genome RNA sequences, to construction of infectious HCV DNA clones, and to use of the clones, or their derivatives, in therapeutic, vaccine, and diagnostic applications. The invention is also directed to HCV vectors, e.g., for gene therapy of gene vaccines.

US Patent:

61271160, Oct 3, 2000

Filed:

Mar 4, 1997

Appl. No.:

8/811566

Inventors:

Charles M. Rice - University City MO
Alexander A. Kolykhalov - St. Louis MO

Assignee:

Washington University - St. Louis MO

International Classification:

C07H 2102
C07H 2104
C12N 510
C12N 1563

US Classification:

435 6

Abstract:

The present invention relates to the determination of an authentic HCV genome RNA sequences, to construction of infectious HCV DNA clones, and to use of the clones, or their derivatives, in therapeutic, vaccine, and diagnostic applications. The invention is also directed to HCV vectors, e. g. , for gene therapy of gene vaccines.

US Patent:

62970038, Oct 2, 2001

Filed:

Jul 18, 1997

Appl. No.:

8/897126

Inventors:

Charles M. Rice - University City MO
Alexander A. Kolykhalov - St. Louis MO

Assignee:

Washington University - St. Louis MO

International Classification:

C12Q 170

US Classification:

435 5

Abstract:

The invention relates to the discovery of a novel RNA sequence at the 3' terminal sequence of hepatitis C virus (HCV) genome RNA. Included in the invention are the 3' sequence, its complement, and their use for nucleic-acid based diagnostics and for developing and evaluating novel anti-HCV therapies. This sequence element, which is conserved among HCV genotypes, is likely to be essential for viral replication, and required for construction of full-length HCV cDNA clones capable of yielding infectious RNA, progeny virus or replication-competent HCV replicons. Such functional clones are useful tools for evaluation of therapeutic approaches and as substrates for developing candidate attenuated or inactivated HCV derivatives for vaccination against HCV.